A detailed history of Becker Capital Management Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Becker Capital Management Inc holds 17,280 shares of GILD stock, worth $1.52 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
17,280
Previous 19,120 9.62%
Holding current value
$1.52 Million
Previous $1.4 Million 15.36%
% of portfolio
0.04%
Previous 0.05%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$63.15 - $72.88 $116,196 - $134,099
-1,840 Reduced 9.62%
17,280 $1.19 Million
Q1 2024

May 15, 2024

SELL
$71.58 - $87.29 $164,920 - $201,116
-2,304 Reduced 10.75%
19,120 $1.4 Million
Q4 2023

Feb 14, 2024

SELL
$73.27 - $83.09 $97,009 - $110,011
-1,324 Reduced 5.82%
21,424 $1.74 Million
Q3 2023

Nov 14, 2023

SELL
$73.94 - $80.67 $441,717 - $481,922
-5,974 Reduced 20.8%
22,748 $1.7 Million
Q2 2023

Aug 11, 2023

SELL
$76.01 - $86.7 $616,517 - $703,223
-8,111 Reduced 22.02%
28,722 $2.21 Million
Q1 2023

May 15, 2023

SELL
$77.31 - $88.08 $8.68 Million - $9.89 Million
-112,280 Reduced 75.3%
36,833 $3.06 Million
Q4 2022

Feb 13, 2023

SELL
$62.32 - $89.47 $6.75 Million - $9.69 Million
-108,303 Reduced 42.07%
149,113 $12.8 Million
Q3 2022

Nov 14, 2022

SELL
$59.54 - $68.01 $445,359 - $508,714
-7,480 Reduced 2.82%
257,416 $15.9 Million
Q2 2022

Aug 04, 2022

SELL
$57.72 - $65.01 $6.69 Million - $7.53 Million
-115,836 Reduced 30.42%
264,896 $16.4 Million
Q1 2022

May 12, 2022

SELL
$57.92 - $72.58 $12,568 - $15,749
-217 Reduced 0.06%
380,732 $22.6 Million
Q4 2021

Feb 08, 2022

SELL
$64.88 - $73.64 $1.31 Million - $1.48 Million
-20,136 Reduced 5.02%
380,949 $27.7 Million
Q3 2021

Oct 14, 2021

BUY
$67.69 - $73.03 $2.47 Million - $2.67 Million
36,499 Added 10.01%
401,085 $28 Million
Q2 2021

Aug 12, 2021

BUY
$63.47 - $69.35 $130,303 - $142,375
2,053 Added 0.57%
364,586 $25.1 Million
Q1 2021

May 13, 2021

BUY
$60.0 - $68.46 $84,960 - $96,939
1,416 Added 0.39%
362,533 $23.4 Million
Q4 2020

Feb 10, 2021

SELL
$56.65 - $64.55 $1.06 Million - $1.21 Million
-18,722 Reduced 4.93%
361,117 $21 Million
Q3 2020

Nov 09, 2020

SELL
$62.1 - $78.08 $463,452 - $582,711
-7,463 Reduced 1.93%
379,839 $24 Million
Q2 2020

Aug 11, 2020

SELL
$72.34 - $84.0 $7.49 Million - $8.7 Million
-103,518 Reduced 21.09%
387,302 $29.8 Million
Q1 2020

May 07, 2020

SELL
$62.63 - $80.22 $12.1 Million - $15.5 Million
-193,012 Reduced 28.23%
490,820 $36.7 Million
Q4 2019

Feb 11, 2020

BUY
$61.62 - $67.78 $6.28 Million - $6.9 Million
101,863 Added 17.5%
683,832 $44.4 Million
Q3 2019

Nov 14, 2019

SELL
$62.51 - $69.0 $9.77 Million - $10.8 Million
-156,325 Reduced 21.17%
581,969 $36.9 Million
Q2 2019

Aug 08, 2019

BUY
$61.87 - $69.38 $367,198 - $411,770
5,935 Added 0.81%
738,294 $49.9 Million
Q1 2019

May 08, 2019

BUY
$62.53 - $70.05 $255,497 - $286,224
4,086 Added 0.56%
732,359 $47.6 Million
Q4 2018

Feb 04, 2019

SELL
$60.54 - $79.0 $1.25 Million - $1.63 Million
-20,585 Reduced 2.75%
728,273 $45.6 Million
Q3 2018

Nov 05, 2018

SELL
$71.28 - $78.92 $149,688 - $165,732
-2,100 Reduced 0.28%
748,858 $57.8 Million
Q2 2018

Aug 03, 2018

BUY
$64.88 - $75.68 $1.23 Million - $1.43 Million
18,918 Added 2.58%
750,958 $53.2 Million
Q1 2018

May 07, 2018

BUY
$72.84 - $88.8 $2.28 Million - $2.78 Million
31,270 Added 4.46%
732,040 $55.2 Million
Q4 2017

Feb 13, 2018

SELL
$71.15 - $83.52 $159,304 - $187,001
-2,239 Reduced 0.32%
700,770 $50.2 Million
Q3 2017

Nov 02, 2017

BUY
$72.11 - $85.47 $1.08 Million - $1.28 Million
15,030 Added 2.18%
703,009 $57 Million
Q2 2017

Aug 11, 2017

BUY
N/A
687,979
687,979 $48.7 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $110B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Becker Capital Management Inc Portfolio

Follow Becker Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Becker Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Becker Capital Management Inc with notifications on news.